NFL BIOSCIENCES overview

NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, has been informed that 50,000 BSPCE company founder warrants (“BSPCE warrants”) held by Mr Bruno Lafont, Chief Operating Officer and co-founder of NFL Biosciences, have been exercised, giving him the right to subscribe 500,000 new...

NFL Biosciences: Recruitment completed for the PRECESTO study PRECESTO clinical trial to demonstrate the potential complementarity of NFL-101 with other smoking cessation treatments: 100% of volunteers recruited and initial results expected in the third quarter of 2023. NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that the final recruitments have been completed for the 34...

NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study, which aims to demonstrate the complementarity of NFL-101 with other smoking cessation treatments NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical medicines for the treatment of addiction, announces the inclusion of the first volunteer in its PRECESTO clinical trial , designed to evaluate the complementarity of its NFL-101 treatment as a smoking cessation...

Tobacco addiction: NFL Biosciences collaborates with the CEA to study the mechanism of action of its drug candidate NFL-101 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces the implementation of a study, with the French Alternative Energies and Atomic Energy Commission (CEA), on the mechanism of action of its drug candidate NFL-101. NFL-Biosciences will use the...

Very successful capital increase for NFL Biosciences with over €3 million raised Strong success of the placement with professional investors with a diversified base of French and international investors for an amount of €2.45 million Exceptional participation of retail investors via the PrimaryBid platform with an offer oversubscribed nearly 3 times and almost 1,000 orders received , for a total amount of €1.6M, with €0.6M being allocated to the retail tranche 1 . Subscription price set...

NFL Biosciences launches a round of fundraising for approximately 2.5 million euros Capital increases as part of a global offer comprising an offer reserved for professional investors and a public offering for retail investors through the PrimaryBid platform. The PrimaryBid Offer will close on January 30 at 10 pm and the Offer reserved for professional investors will close on January 31 , 2023 before start of trading (subject to early closure). Price range of €2.08 to €2.35 per new share,...

NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants recruited Main results expected by the end of 2023 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, is announcing that the CESTO II Phase II/III clinical trial to assess the efficacy and safety of its NFL-101 smoking cessation treatment is progressing...

NFL BIOSCIENCES: CLINICAL TRIAL APPROVED TO DEMONSTRATE THE COMPLEMENTARITY OF NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that its clinical trial to assess the complementarity of NFL-101 as a smoking cessation treatment with other smoking cessation treatments and particularly nicotine substitutes, has been approved by the...